Advanced Solid Cancers
Conditions
Brief summary
This is a phase 1b, open label trial of ADI-PEG 20 (36 mg/m2) weekly in combination with pembrolizumab (1 and 2 mg/kg or 200 mg) every three weeks. Assessment of safety and tolerability of drug combination
Detailed description
This is an open-label, phase 1b trial of ADI-PEG 20 in combination with pembrolizumab in subjects with advanced cancers. Dose escalation will occur using a 3 + 3 + 3 design. The first subject in a dose escalation cohort must have had treatment with ADI-PEG 20 + pembrolizumab with a week of follow up) before the next 2 subjects are enrolled. Thus subjects 2 and 3 may be enrolled on day 8 if there is no dose limiting toxicity (DLT) in subject 1. No additional delay is required between treating subjects 4 to 6 or 7 to 9 in an expanded cohort. Before proceeding to the next cohort dose level, the first 3 eligible subjects in each cohort will have received at least 21 days of treatment (i.e. at least 2 of the expected 3 doses of ADI-PEG 20 + one dose of pembrolizumab).
Interventions
DRUGADI PEG20
ADI is a recombinant protein cloned from M. hominis and produced in E. coli, and conjugated with PEG of 20,000 mw. Thus ADI-PEG 20 is an arginine degrading enzyme, ADI, coupled to PEG.
DRUGPembrolizumab
Pembrolizumab is a PD-1 blocking antibody indicated in the USA for the treatment.
Sponsors
Polaris Group
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
Select Inclusion Criteria: 1. Histologically confirmed diagnosis of advanced solid tumor. 2. Prior failure of a systemic treatment approved by the health authority in the country where the study will be enrolling. Such subjects may also have been treated with radiotherapy, local therapy or surgery. 3. Measurable disease using RECIST 1.1 criteria. 4. Age ≥ 18 years. Select
Exclusion criteria
1. Subjects with history of another primary cancer, including co-existent second malignancy, with the exception of: a) curatively resected non-melanoma skin cancer; b) curatively treated cervical carcinoma in situ; or c) other primary solid tumor with no known active disease present or in the opinion of the investigator will not affect patient outcome. 2. Subjects who had been treated with ADI-PEG 20 previously. 3. History of seizure disorder not related to underlying cancer. 4. Known allergy to pegylated compounds. 5. Known allergy to E. coli drug products (such as GMCSF).
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Number of Participants with Adverse Events as a Measure of Safety and Tolerability of ADI-PEG 20 in combination with Pembrolizumab in Advanced Solid Cancers | Up to 36 months | Number of participants with treatment-related adverse events and severity this is graded by CTCAE and MedDRA for Coding |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Number of Participants with PFS with Combination ADI-PEG 20 and Pembro. | Assessments ever 9 weeks for 12 months | Progression Free Survival determined by RECIST 1.1 |
| Number of Participants with RR with Combination ADI-PEG 20 and Pembro. | Assessments ever 9 weeks for 12 months | Response Rate determined by RECIST 1.1 |
Other
| Measure | Time frame | Description |
|---|---|---|
| Overall Survival | 12 months after end of treatment | Follow-Up by Phone or Clinic Visit |
Countries
Taiwan
Outcome results
None listed